Mass spectrometric protein maps for biomarker discovery and clinical research.
about
Advances in targeted proteomics and applications to biomedical researchExtending the limits of quantitative proteome profiling with data-independent acquisition and application to acetaminophen-treated three-dimensional liver microtissues.Ranking Fragment Ions Based on Outlier Detection for Improved Label-Free Quantification in Data-Independent Acquisition LC-MS/MS.High-precision iRT prediction in the targeted analysis of data-independent acquisition and its impact on identification and quantitation.Glycoproteomic analysis of prostate cancer tissues by SWATH mass spectrometry discovers N-acylethanolamine acid amidase and protein tyrosine kinase 7 as signatures for tumor aggressiveness.Exosomes from metastatic cancer cells transfer amoeboid phenotype to non-metastatic cells and increase endothelial permeability: their emerging role in tumor heterogeneityAnalytical challenges translating mass spectrometry-based phosphoproteomics from discovery to clinical applications.Modules, networks and systems medicine for understanding disease and aiding diagnosis.A repository of assays to quantify 10,000 human proteins by SWATH-MS.Quantitative variability of 342 plasma proteins in a human twin population.Processing strategies and software solutions for data-independent acquisition in mass spectrometry.Comparative proteomic analysis of serum diagnosis patterns of sputum smear-positive pulmonary tuberculosis based on magnetic bead separation and mass spectrometry analysis.Using data-independent, high-resolution mass spectrometry in protein biomarker research: perspectives and clinical applications.Discovery and targeted proteomics on cutaneous biopsies infected by borrelia to investigate lyme disease.Online Peptide fractionation using a multiphasic microfluidic liquid chromatography chip improves reproducibility and detection limits for quantitation in discovery and targeted proteomics.Applying SWATH Mass Spectrometry to Investigate Human Cervicovaginal Fluid During the Menstrual Cycle.SWATH-MS as a tool for biomarker discovery - from basic research to clinical applications.Analysis of Major Histocompatibility Complex (MHC) Immunopeptidomes Using Mass Spectrometry.The clinical impact of recent advances in LC-MS for cancer biomarker discovery and verification.Next-generation snake venomics: protein-locus resolution through venom proteome decomplexation.Unraveling the exercise-related proteome signature in heart.Coupling enrichment methods with proteomics for understanding and treating disease.Unravelling the proteome of degenerative human mitral valves.Assessment of simpler calibration models in the development and validation of a fast postmortem multi-analyte LC-QTOF quantitation method in whole blood with simultaneous screening capabilities using SWATH acquisition.Targeted proteomics of solid cancers: from quantification of known biomarkers towards reading the digital proteome maps.SWATH Mass Spectrometry for Proteomics of Non-Depleted Plasma.Blood biomarker discovery in drug-free schizophrenia: the contributionof proteomics and multiplex immunoassays.Advances in mass spectrometry-based cancer research and analysis: from cancer proteomics to clinical diagnostics.Proteomics discovery of chemoresistant biomarkers for ovarian cancer therapy.Current trends in quantitative proteomics - an update.Qualification and Verification of Protein Biomarker Candidates.Mass spectrometry-assisted gel-based proteomics in cancer biomarker discovery: approaches and application.Biomarkers for Hepatocellular Carcinoma.Low T3 State Is Correlated with Cardiac Mitochondrial Impairments after Ischemia Reperfusion Injury: Evidence from a Proteomic Approach.Is there a future for metabotyping in clinical laboratories?Multiplexed MRM-based assays for the quantitation of proteins in mouse plasma and heart tissue.Targeted Proteomics for Multiplexed Verification of Markers of Colorectal Tumorigenesis.Comparison of targeted proteomics approaches for detecting and quantifying proteins derived from human cancer tissues.Multiomics tools for the diagnosis and treatment of rare neurological disease.Large-scale multiplex absolute protein quantification of drug-metabolizing enzymes and transporters in human intestine, liver, and kidney microsomes by SWATH-MS: Comparison with MRM/SRM and HR-MRM/PRM.
P2860
Q28066912-D2849273-722D-4D7A-97C7-38463145D10CQ30901756-66AF3F52-E7B5-4E96-A784-938220743327Q30998330-CEBF5E77-35F5-4A90-A47B-FC1FF465558FQ31099853-ACC86EAC-9A6C-4663-BFD0-C6555A1794F5Q33850638-3220C0B5-C7D7-4A92-983C-5B815C4AA335Q33875354-EEF277AD-0889-4370-B9B4-BCF1BC4B6887Q34604043-950F8F60-5BD9-4C13-B1DA-F05949200D5DQ34624769-3FFCA442-6D9A-4D4F-9E6C-41E82BE44DD6Q35066504-7CF43C91-6C62-4398-9E80-369345DA0F5EQ35174121-E6148349-E798-4164-89FC-69090D5FE397Q35455128-2A177EB4-038A-40E5-A2E3-1689248DFF4AQ35479908-A57AF5AA-D135-4CF6-9B01-CD7AE0DE52D8Q35518214-5D694EC8-7F5D-4F33-B7D3-C6DDD4C3B8D1Q35583325-5428B59C-4004-43EA-8C37-A8DA16AC9117Q35596896-ABAE3754-B978-4068-AE80-177427E95B53Q35673557-D693A524-42F7-4349-85EE-456F477A426AQ36262132-ED3B27B2-0398-4D6A-A76C-8C077A3C3293Q36604367-473BB6B2-EA40-4CF0-8C92-10F552F7043FQ36771005-8B216083-E6BC-4C02-81FB-7DEA0F38DC7DQ38200131-9BB565A4-BD8E-43D1-B101-1F1135620CB6Q38283265-84EB4714-7040-4962-BC2F-2DE8C077C006Q38293824-5A635630-F8E3-4612-A9D5-50199821948DQ38412482-2CAB4F06-8012-4E56-AA63-1C113213FAF3Q38602710-6FAC13B6-395D-4D16-AE39-2D05655D66CCQ38604366-56F76F68-798C-4937-AC73-82DB83A3B029Q38694922-D62CC814-D83F-4F13-A8D1-5B75BCA976F8Q38807041-2A5E2A40-4E43-48F7-A099-B4A98EB162A6Q38816181-51A70D7C-9BC0-478E-A7F1-0A1898F3DBB2Q38824059-D8E66088-4D94-4BD7-8F8A-CC1C8707A27EQ38832695-A64EFD85-A5A0-4B7C-A004-4E927A7EC635Q39099858-7EC8934B-0984-4600-A0C4-6A483245FB12Q41173805-0AD91C62-F16A-4CCD-ADAF-7B8B0881887BQ42176411-3FB24CF3-382D-4084-8E58-42F08474CB69Q43152861-B8AA770D-1653-4218-95B5-810CC281891BQ48645828-8832020A-7898-456F-90C8-FA4A59C15FEBQ51149956-EA9F1615-8BE2-4202-B489-11DD70BCDE43Q51210845-2EBFE968-BB5A-4050-87D3-315FC94E9F74Q51267763-FE248BE3-14CB-42FD-96D7-731543819EDAQ52656884-5729CE5B-6440-4C88-8572-26775859F51DQ53048764-C4036CAE-C445-4D03-B145-D671E0C32231
P2860
Mass spectrometric protein maps for biomarker discovery and clinical research.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 21 October 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Mass spectrometric protein maps for biomarker discovery and clinical research.
@en
Mass spectrometric protein maps for biomarker discovery and clinical research.
@nl
type
label
Mass spectrometric protein maps for biomarker discovery and clinical research.
@en
Mass spectrometric protein maps for biomarker discovery and clinical research.
@nl
prefLabel
Mass spectrometric protein maps for biomarker discovery and clinical research.
@en
Mass spectrometric protein maps for biomarker discovery and clinical research.
@nl
P2860
P50
P921
P1476
Mass spectrometric protein maps for biomarker discovery and clinical research.
@en
P2093
Ruedi Aebersold
P2860
P304
P356
10.1586/14737159.2013.845089
P577
2013-10-21T00:00:00Z
2013-11-01T00:00:00Z